ERYTECH Announces a Poster Presentation for TRYbeCA1 at the ASCO 2020
Greater than 50% enrollment achieved in ongoing Phase 3 trial of eryaspase in pancreatic cancer
Trial in Progress Poster selected for inclusion in Poster Walk
TRYbeCA1 is planned to enroll approximately 500 patients in approximately 100 clinical sites in
Along with the U.S., clinical trial authorizations have been obtained for TRYbeCA1 in eleven European countries with the trial actively enrolling patients in more than 50 clinical sites.
“TRYbeCA1 continues to remain on track with well over half of the planned number of patients having been enrolled in the trial. We are encouraged by the level of enthusiasm from both European and US investigators and growing interest in TRYbeCA1 as highlighted by the inclusion of our poster in the Poster Walk at this meeting,” stated
“There remains a high unmet need for advances in the treatment of advanced pancreatic cancer,” stated Dr.
Details of the poster presentation:
TRYbeCA1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).
Level 1 West Hall,
Abstract: TPS783
Poster: Q4
About ERYTECH: www.erytech.com
ERYTECH is a clinical-stage biopharmaceutical company developing innovative red blood cell-based therapeutics for severe forms of cancer and orphan diseases. Leveraging its proprietary ERYCAPS platform, which uses a novel technology to encapsulate drug substances inside red blood cells, ERYTECH is developing a pipeline of product candidates for patients with high unmet medical needs. ERYTECH’s primary focus is on the development of product candidates that target the altered metabolism of cancer cells by depriving them of amino acids necessary for their growth and survival.
The Company’s lead product candidate, eryaspase, which consists of L-asparaginase encapsulated inside donor-derived red blood cells, targets the cancer cell’s altered asparagine and glutamine metabolism. Eryaspase is in Phase 3 clinical development for the treatment of second-line pancreatic cancer and in Phase 2 for the treatment of first-line triple-negative breast cancer. An investigator-sponsored Phase 2 study in second-line acute lymphoblastic leukemia is ongoing in the Nordic countries of
ERYTECH produces its product candidates for treatment of patients in
ERYTECH is listed on the Nasdaq Global Select Market in the United States (ticker: ERYP) and on the Euronext regulated market in Paris (ISIN code: FR0011471135, ticker: ERYP). ERYTECH is part of the CAC Healthcare, CAC Pharma & Bio, CAC Mid & Small, CAC All Tradable, EnterNext PEA-PME 150 and Next Biotech indexes.
CONTACTS
ERYTECH Eric Soyer CFO & COO |
LifeSci Advisors, LLC Investor Relations Corey Davis, Ph.D. |
NewCap Mathilde Bohin / Louis-Victor Delouvrier Investor relations Nicolas Merigeau Media relations |
+33 4 78 74 44 38 investors@erytech.com |
+1 (212) 915 - 2577 cdavis@lifesciadvisors.com |
+33 1 44 71 94 94 erytech@newcap.eu |
Forward-looking information
This press release contains forward-looking statements, forecasts and estimates with respect to the clinical results from and the development plans of eryaspase, business and regulatory strategy, expansion of manufacturing capacity and anticipated future performance of ERYTECH and of the market in which it operates. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, “believes”, “anticipates”, “expects”, “intends”, “plans”, “seeks”, “estimates”, “may”, “will” and “continue” and similar expressions. All statements contained in this press release other than statements of historical facts are forward-looking statements, including, without limitation, statements regarding the ERYTECH’s business strategy including its clinical development of eryaspase; the status of the TRYbeCA1 trial including the timeline for patient enrollment, expansion of trial into
PDF available at: http://ml.globenewswire.com/Resource/Download/877fd1f7-ffc7-49d9-82ac-a573a1f09efd
Source: Erytech Pharma S.A.